In order to minimize the impact of a pandemic on the economy, which would be more effective: a lockdown or letting individuals spontaneously reduce their risk of infection?
Incyte gets another graft-versus-host disease drug approval, this time with partner Syndax
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS